Vol 30 No 10

The authors evaluate the effects of nicotine and cannabis on neurocognitive function in individuals with schizophrenia and review potential pharmacological treatment strategies.

This child's behaviors suggested ADHD-combined or primarily hyperactive type and conduct disorder. However, there was a strong history of trauma and affective disturbance. A structured interview format indicated that he formally met criteria for both PTSD and mixed episode. Without this format, features defining these disorders might have been missed and the child treated only for ADHD.

Undoubtedly there will be problems with some of the additions to DSM-5, with some of the combinations, with some of the new nomenclature, and with some of the new criteria sets. But practitioners will find most of DSM-5 to be well considered and well written. It is unfortunate, however, that much of its nomenclature is out of sync with the rest of medicine.

This article explores the current state of knowledge regarding personalized medicine in psychiatry and discusses how the tools might be used to help psychiatrists understand the components of their patients’ unique endophenotypic profiles.

There are a number of well-established niches in psychiatry, from forensics to addictions to LGBT. This author relates how she established her niche as a sports psychiatrist.

There have been considerable advances in the research on and clinical use of neurostimulation for psychiatric disorders, especially mood disorders and MDD. Three of the most recognized are reviewed here. An experimental new treatment-- trigeminal nerve stimulation-- is also briefly discussed.

Clearly, old age is associated with unavoidable decline but in some instances can be mitigated by mental and physical exercise and social activity. How is the preservation of function despite illness and decline accomplished? Insights here. . .

Psychiatric Times asked this psychiatrist to compile and edit a series worthy of its readers’ attention. We hope you find that this special section has achieved the literary and professional standards we set.

I never take calls when I'm with a patient, except today when the phone rings from Boston-liver mets on his scan, biopsy tomorrow...

Despite pharma's retreat and the many challenges in psychiatric drug development -- as detailed here -- the current psychiatric drug pipeline is not totally dry.

Psychiatric Times is conducting its 2013 ethics survey. We invite you to share your perspective and participate in the survey.